Spotlight On... Bayer, coveting top spots in animal and consumer health, may eye deals for Zoetis, Pfizer OTC; EMA warns of PML, cancer risks from Novartis' Gilenya; GSK adds Bristol's HIV pipeline assets; and more...

Bayer's position in the OTC and animal health markets has slipped thanks to some big-time consolidation moves from its rivals. But the German pharma may have a big-time move of its own up its sleeve, Reuters sources say--and it could include animal health leader Zoetis ($ZTS) or Pfizer's ($PFE) consumer offerings. More from FiercePharma

> The Europeans Medicines Agency (EMA) has added risks of basal cell carcinoma and rare brain disease PML to the product information of Novartis' ($NVS) multiple sclerosis pill Gilenya. More

> In Big Pharma's latest effort to bulk up where it's strongest, GlaxoSmithKline ($GSK) has added Bristol-Myers Squibb's ($BMY) HIV pipeline to its ViiV Healthcare portfolio. More

> Stirling Anglian Pharmaceuticals, which paid for NHS budget holders to go on a luxury trip to the German spa resort of Baden-Baden, has been heavily reprimanded by the U.K.'s industry watchdog, the Prescription Medicines Code of Practice Authority. More

> Proton-pump inhibitors, routinely prescribed to hospitalized patients, may raise the risk of death. More

And Finally... Reports have emerged that the mcr-1 gene, which confers resistance to an important antibiotic of last resort, has been found in bacteria previously collected in a handful of countries around the world. More

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.